A 42-year-old manhad biochemical and somatic abnormalities compatible with pseudohypoparathyroidism type I (PsHP) and also had high plasma renin activity (PRA). After 1,25-dihydroxyvitamin D (calcitriol) supplementation the systolic/diastolic blood pressure, assessed by 24-hour non-invasive ambulatory blood pressure monitoring, was reduced from 145/96 mmHg to 128/85 mmHg with normalization of the serum calcium level and its related hormones, as well as decreased PRA. Calcitriol supplementation successfully reduced the blood pressure in this patient with PsHP and a high PRA, suggesting that calcium-related hormones and/or the renin-angiotensin system were involved in lowering the blood pressure. (Internal Medicine 38: 31-35, 1999) 
Introduction
Pseudohypoparathyroidism type I (PsHP) is a relatively rare disease caused by target organ resistance to parathyroid hormone (PTH). In 1988, it was reported that the prevalence of hypertension was higher in this disease than in the general population (1) and it is thought to be a cause of secondary hypertension (2) . However, little information is available about the mechanismof hypertension in this disease. Brickmanet al have reported that this newly identified form of endocrinerelated hypertension is strongly linked to obesity but is distinct from obesity-related essential hypertension in its alterations of hormonal responses (1) . PsHP is characterized by an elevated serum PTH level and hypocalcemia, while primary hyperparathyroidism is characterized by an elevated serum PTHlevel and hypercalcemia, as well as a high prevalence of hypertension. Idiopathic hypoparathyroidism is characterized by a decreased serum PTHlevel and hypocalcemia and is associated with a low prevalence of hypertension (1) . The relationship between hypertension and serum PTHand calcium levels suggests that a high PTHlevel may cause hypertension in PsHP. The association between blood pressure and PTHis well known in normotensives (3, 4) , hypertensives (5) (6) (7) (8) , and old aged persons (9) . Although vitamin D therapy can ameliorate the elevated serum PTHlevel in PsHP (10), there are no reports whether such supplementation is also effective in reducing blood pressure in PsHP.
Here, we present a patient with PsPHtype I whohad a reduction in blood pressure with vitamin D supplementation.
Wealso discuss the role of the renin-angiotensin system and calcium-related hormones in the hypotensive mechanism.
Case Report
The patient was a 42-year-old Japanese man who had been diagnosed with high blood pressure at a screening examination at age 30. The examination at the HanamakiGeneral Hospital showed hypertension ( 170/1 10 mmHg)with high plasma renin activity (6.8 ng/ml/h) and hypocalcemia (7. 1 mg/dl, after correction for albumin). Antihypertensive treatment was started at that time. He worked at a business after graduation from high school; he had no history of mental or emotional problems. He has had no symptoms of hypocalcemia. Amonghis family members, his mother was short (139 cm). However, her serum calcium and Pi were found to be normal. Pi were poor in response to PTH injection (Fig. 1) . The difference between (U4+U5) and (U2+U3) was 31 mg Pi/2h (normal range: >35). The difference between U4 and U3 was 0.37 jimol of cyclic AMP/h(normal range: >1) and the ratio of U4 to U3 was 3.8 (normal range: >10). Bilateral calcification of basal ganglia was detected by computed tomography (Fig. 2) . Radiography of the hands showed no abnormality including brachydactyly.
We performed abdominal aortography by intra-arterial digital subtraction angiography whether the patient had renovascular hypertension due to his high PRA.There were no abnormal findings in either renal artery. He was placed on a diet containing 7 g of sodium chloride (NaCl), 600 mg to 700 mg of calcium, and 1,000 mg to 12,000 mg of phosphorus. He was asked to keep regular hours including awaking time of 6:00 AMand a bed time of 9:00 PM. He was asked to walk 5,000 steps a day measured with a pedometer during the hospitalization. this treatment, we evaluated renal function by the method of Lawton et al using standard clearance techniques (12) . On the next day, we sampled blood for serum calcium, Pi, intact-PTH, calcitriol, and PRAafter the patient was recumbent for 30 minutes. Blood sampling for PRAwas obtained after 30 minutes of standing. After sampling, 24-hour ambulatory blood pressure monitoring was performed as we reported previously (13) . The same examinations were performed 2 weeks later during therapy. Figure 3 shows ambulatory blood pressure monitoring before and during therapy. Although the average systolic/diastolic blood pressure was 145/96 mmHgbefore therapy, the systolic/diastolic blood pressure decreased to 1 28/ 85 mmHg after 2 weeks of the therapy. The dipper ratio of a reflection of the circadian blood pressure rhythmwascalculated as lOOx (mean value obtained from 6:00 AMto 9:30 PM) / (mean value obtained from 10:00 PMto 5:30 AM).The systolic/ diastolic dipper ratio (%) was 96/92 before therapy, and 93/90 after 2 weeks of therapy, respectively. Table 2 shows that therapy caused normalization of serum albumin-corrected calcium, intact-PTH, and PRA. PRAin standing was also lower during therapy than before therapy. Renal function was unaffected by therapy.
Discussion
This patient showed the typical biochemical abnormalities associated with PsHP including poor renal response to PTH. Features of Albright' s hereditary osteodystrophy (round face, short stature, obesity) were consistent with an la subtype of PsHP, although brachydactyly was absent and guanine nucleotide regulatory coupling protein activity was not measured. There was no resistance to other hormones, a feature that had been described previously (14) .
The PRAlevel, measured in the recumbent position, was 2.6 Circadian blood pressure rhythm ng/ml/h while the patient received a 7 g NaCl diet before calcitriol supplementation. The meanPRAlevel was 0.74 ± 0.83 ng/ml/h in 22 male patients aged 35-55 years old with essential hypertensionundersimilar conditions(unpublished work), indicating that our patient had a relatively high PRA. Renovascular hypertensionwasruled out by angiography. Since calcitriol supplementationreducedthe PRAwith concomitantnormalizationof the serumcalciumandPTH,it was thoughtthat these variables were, at least in part, responsiblefor the high PRAlevel. Adecrease in intra-juxtaglomerular calcium increases renin secretion (15) . Alternatively, the decreased PTHmayhave reduced PRA,since PTHhas been shownto stimulate renin release directly ( 1 6). Alsoan increased calcitriol mayhavecauseda reducedPRAlevel, since calcitriol has been reported to inhibit renin release directly (17, 18) . Themostimportantfinding wasthat calcitriol supplementation reduced the blood pressure in this case. Ambulatoryblood pressuremonitoringwasmeasuredbefore andduringthe therapy undercontrolledconditionswherethe patient wasaskedto keep regular hours and exercise activity, and to keep NaClintake constant, factors knownto affect blood pressure levels (19) .
There are several possible explanations for the reduction in blood pressure, including inhibition of the renin-angiotensin systemandnormalizationof serumPTH. Inhibition of the secretion of the parathyroid hypertensive factor (20) , whichhas beenthought to be secreted simultaneouslyfromthe parathyroid gland, mayhave been responsible for the blood pressure reduction. It is also possible that calcitriol mayhaveloweredthe bloodpressure directly. Specific receptors for calcitriol have beenfound in tissues involved in blood pressure regulation in vascularsmoothmuscle (21) , althoughit remainsunclear whetherthe binding leads to blood pressure reduction.
In conclusion, our results suggestthat calcitriol supplementation lowers blood pressure, normalizes serumPTHand calciumlevels, and decreases high PRAlevel in PsPH.
